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In MS, B cells survive peripheral tolerance checkpoints to mediate local inflammation,
but the underlying molecular mechanisms are relatively underexplored. In mice, the MIF
pathway controls B-cell development and the induction of EAE. Here, we found that MIF
and MIF receptor CD74 are downregulated, while MIF receptor CXCR4 is upregulated in
B cells from early onset MS patients. B cells were identified as the main immune subset
in blood expressing MIF. Blocking of MIF and CD74 signaling in B cells triggered CXCR4
expression, and vice versa, with separate effects on their proinflammatory activity, pro-
liferation, and sensitivity to Fas-mediated apoptosis. This study reveals a new reciprocal
negative regulation loop between CD74 and CXCR4 in human B cells. The disturbance of
this loop during MS onset provides further insights into how pathogenic B cells survive
peripheral tolerance checkpoints to mediate disease activity in MS.
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 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
MS is a chronic autoimmune disease of the CNS, in which infiltrat-
ing proinflammatory immune cells mediate local pathology [1].
The strong effects of anti-CD20 monoclonal antibody therapy in
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MS patients demonstrate a key role for peripheral B cells during
the pathogenesis [2]. Immature B cells survive peripheral toler-
ance checkpoints inMS [3], but underlyingmechanisms are poorly
understood.
An important factor associated with chronic inflammation and
cell survival is MIF [4]. In the animal model of MS, i.e. EAE,
MIF levels are increased in the CNS [5]. Furthermore, anti-MIF
treatment prevents disease onset and improves the course of the
disease by decreasing the expression of VCAM-1, which impairs
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the homing of neuroantigen-specific T cells to the CNS [6]. Which
and how immune subsets are regulated by MIF to promote disease
activity in MS patients remains to be determined.
In murine B cells, triggering of the cognate receptor of MIF,
CD74 (invariant chain), results in enhanced proliferation and
proinflammatory cytokine production via NF-κB [7, 8]. Besides
functioning as an MHC class II chaperone protein, CD74 also has
an MHC class II-independent role in B-cell maturation [9]. Inter-
estingly, MIF is also a noncognate ligand for chemokine receptor
CXCR4 [10], which probably cooperate with CD74 to regulate
B-cell development and function through MIF [11–13].
This study explores whether MIF, CD74, and CXCR4 expression
in B cells is associated with early MS disease activity, and how the
regulation and downstream effects of MIF receptors CXCR4 and
CD74 affect human B-cell function. We show that MIF and CD74
are downregulated and CXCR4 is upregulated in blood B cells from
early MS patients. This is dependent on a B cell-intrinsic negative
regulation loop between MIF, CXCR4, and CD74, which mediates
their proinflammatory activity, proliferation, and sensitivity to Fas-
mediated apoptosis.
Results
The expression ratio of MIF receptors CXCR4 and
CD74 on B cells is increased during rapid MS onset
To determine whether the B cell-intrinsic MIF pathway is differ-
entially regulated in early MS, we assessed the expression levels
of MIF receptors CXCR4 and CD74 on blood B cells of relapsing-
remitting MS (RRMS) patients and healthy controls (HC). CXCR4
was 1.4-fold increased on B cells from 15 RRMS patients compared
to 15 age- and gender-matched HC (p = 0.002, Fig. 1A, B, and D),
which was reproduced and validated in additional cohorts (Sup-
porting Information Fig. 1A and B). In contrast, CD74 expression
was 1.4-fold reduced on B cells in RRMS versus HC (p = 0.038,
Fig. 1A, C, and E). The ratio of CXCR4 and CD74 expression lev-
els on B cells was even further enhanced in RRMS (2.1-fold, p =
0.004; Fig. 1F; Supporting Information Fig. 1C and D), suggesting
that both MIF receptors are dysregulated on a per-patient basis.
Next to RRMS patients, patients with clinically isolated syn-
drome (CIS), a first manifestation of suspected MS [14], were
analyzed. Similar to RRMS, B cells from CIS patients with a very
rapid onset of clinically definite MS (CDMS) (“high-risk CIS,” n =
16) showed 1.5-fold increased CXCR4 (p = 0.014, Fig. 2A) and
1.3-fold reduced CD74 surface levels (p = 0.004, Fig. 2B) com-
pared to CIS patients with slow or no onset of CDMS (“low-risk
CIS,” n = 17). This resulted in strongly elevated CXCR4/CD74
expression ratios per patient in the high-risk CIS group (2.5-fold;
Fig. 2C). In CIS, a negative correlation was found between CXCR4
and CD74 levels on B cells (r = –0.44, P = 0.01; Fig. 2D), and
CXCR4/CD74 expression ratios positively associated with fatigue
(r = 0.53, P = 0.003; Fig. 2E), an independent predictor of rapid
CIS to CDMS transition [15].
In RRMS and high-risk CIS blood, transitional
(IgM+CD27−CD38hiCD24hi) as well as naive mature
(IgM+CD27−CD38−/dim) B-cell subsets displayed the high-
est CXCR4/CD74 expression ratios as compared to class-
switched (CD27+/CD27− IgG+ and IgA+) and nonclass-switched
(IgM+CD27+) memory subsets (Fig. 3; Supporting Information
Fig. 2), implying that the CXCR4hiCD74lo phenotype of B cells in
early MS reflects a more immature state. These data demonstrate
that MIF receptors CXCR4 and CD74 are inversely expressed on
B cells, which is dysregulated during early disease onset in MS.
MIF is predominantly expressed by B cells in healthy
blood and downregulated in early MS patients
MIF levels in both serum and plasma were not different between
CIS patients and healthy controls (Fig. 4A and Supporting Infor-
mation Fig. 3A) or high-risk and low-risk CIS subgroups (Fig. 4B
and Supporting Information Fig. 3B), and did not correlate with
CXCR4 and CD74 expression levels on B cells from the same indi-
viduals (Supporting Information Fig. 3C and D).
However, among blood immune subsets, MIF mRNA was pre-
dominantly expressed by B cells compared to paired T cells, mono-
cytes and dendritic cells (Fig. 4C), but downregulated in B cells
from RRMS patients versus HC (p < 0.01) and even further in B
cells of CIS patients (CIS vs. HC, p < 0.0001; CIS vs. RRMS, p
< 0.01; Fig. 4D). We found no differences in MIF mRNA levels
between B cells from low-risk and high-risk CIS subgroups (Fig.
4E). Low MIF mRNA levels corresponded to high CXCR4/CD74
surface expression ratios in B cells of patients and controls (p =
0.005; Fig. 4F). This point to the existence of a disturbed regula-
tion loop between MIF and MIF receptors in B cells of early MS
patients.
MIF, CD74, and CXCR4 are part of a reciprocal
negative regulation loop in human B cells
In vitro, B cells showed enhanced MIF expression and secretion
after activation with anti-IgM, which was comparable between
patients and controls (Fig. 5A and B). To determine potential
crosstalk between MIF, CXCR4, and CD74, we used the specific
MIF inhibitor ISO-1 [16] to block MIF-mediated signaling in in
vitro-activated B cells. ISO-1 treatment of these B cells resulted in a
CXCR4 upregulation and CD74 downregulation (Fig. 5C), reflect-
ing the inverse correlation betweenMIF and CXCR4/CD74 expres-
sion levels in B cells ex vivo (Fig. 4F). In parallel to this, in the
human B-cell line Raji, which abundantly expresses CD74 [17], the
percentage of CD74hi cells decreased after MIF knockdown using
three distinct shRNA constructs (Fig. 5D and E). This indicates
that CXCR4 and CD74 surface expression is inversely regulated by
endogenous MIF in B cells. After treatment with anti-CD74 anti-
body (LN2), CXCR4 surface expression was increased, whereas
MIF expression was reduced in in vitro-activated B cells (Fig. 5F
andH). Vice versa, activated B cells treatedwith CXCR4 antagonist
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Figure 1. CXCR4 upregulation and CD74 downregulation on B cells of clinically definite MS patients. (A) Gating strategy for CD19+ B cells. (B and
C) representative histograms of CXCR4 (B) and CD74 (C) expression levels in HC and RRMS. (D–F) Expression of MIF receptors CXCR4 (D) and CD74
(E) and their ratios (F) on blood B cells from 15 RRMS patients and 15 age- and gender-matched healthy controls (HC) as determined by FACS. Data
were measured in three individual experiments, with 5 HC and 5 RRMS patients per experiment. Data are shown as mean ± SEM. Unpaired t-tests
were used to compare groups. *p < 0.05, **p < 0.01.
AMD3100 [18] showed increased CD74 and MIF levels (Fig. 5G
and H). These data demonstrate that MIF, CD74, and CXCR4
expression in human B cells is tightly and mutually controlled.
CXCR4/CD74 controls the inflammatory, proliferative,
and Fas-mediated apoptotic potential of B cells
To determine how the reciprocal negative regulation of CD74 and
CXCR4 is associated with the function of B cells, we compared the
proinflammatory, proliferative, and survival capacity of in vitro-
activated B cells before and after blocking of these MIF receptors.
Treatment of these B cells with anti-CD74 antibody LN2 (24 h)
suppressed the induction of proinflammatory genes NFKB1, IL6,
and TNF (Fig. 6A). This was not found in in vitro-activated B
cells treated with CXCR4 antagonist AMD3100 (Fig. 6A). These
differences were verified on protein level (Supporting Information
Fig. 4). Also B-cell proliferation was inhibited after treatment for
3 days with LN2 antibody and not with AMD3100, as determined
by CFSE labeling (Fig. 6B and C). Finally, surface expression of
the death receptor Fas (CD95) was triggered in AMD3100- and
not in LN2-treated B cells after 3 days of activation (Fig. 6D).
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Figure 2. High CXCR4/CD74 expression ratios on B cells of CIS patients associate with rapid MS diagnosis. Expression of MIF receptors CXCR4 and
CD74 and their ratios on blood B cells of 17 low-risk CIS and 16 high-risk CIS patients (A–C), as determined by FACS. Gating on CD19+ B cells is
depicted in Fig. 1. Data were measured in nine individual experiments, with 1–2 low-risk CIS and 1–2 high-risk CIS patients were measured per
experiment. Data are shown as mean ± SEM. Unpaired t-tests were used to compare groups. (D) Correlation between CXCR4 and CD74 expression
on B cells in CIS patients (n = 33). (E) Correlation between CXCR4/CD74 surface expression ratios on B cells and fatigue severity scores (FSS) for CIS
patients (n = 30). r = Pearson’s correlation coefficient (D) or Spearman correlation (E). *p < 0.05, **p < 0.01, ***p < 0.001.
These results imply that in humans, CD74 primarily boosts the
proinflammatory and proliferative capacity of B cells, while CXCR4
makes B cells less sensitive for Fas-mediated apoptosis [19].
Discussion
The aim of this study was to elucidate the impact of the B-cell
intrinsic MIF pathway on early disease onset in MS patients.
We demonstrate that decreased CD74 and increased CXCR4
expression on B cells in blood are associated with early MS diag-
nosis. This was shown for CIS patients who will rapidly develop
MS as well as for clinically definite MS patients. In vitro experi-
ments supported the inverse regulation of MIF/CD74 and CXCR4
expression in B cells ex vivo, which differentially controlled their
proinflammatory capacity, proliferation, and sensitivity to Fas-
mediated apoptosis (Supporting Information Fig. 5). The observed
CXCR4hiCD74lo B-cell phenotype in early MS blood points to the
presence of more immature B-cell populations with senescent
features that survived peripheral tolerance checkpoints in MS [3].
There are several lines of evidence implying that CD74 down-
regulation and CXCR4 upregulation disrupt the selection of imma-
ture B cells. During B-cell development, “new emigrant” transi-
tional subsets in blood are negatively selected in secondary lym-
phoid organs for autoreactive clones before developing into naive
mature subsets. B cells in CD74-deficient mice revealed an arrest
at the transitional stage [20] and a reduced lifespan [21]. Con-
sistently, decreased CD74 expression impaired B-cell maturation
in patients with X-linked lymphoproliferative disease [22]. Both
cell autonomous and nonautonomous roles of CD74 could explain
these defects in B-cell development. As a cell surface receptor,
CD74 triggers B-cell proliferation in mice [8] and humans (cur-
rent study), supporting the lowered proliferative capacity of naive
(CD74lo) versus memory (CD74hi) populations [23]. The reduced
expression of CD74 on B cells in early MS blood thus might reflect
a functional state of anergy, contributing to the persistence of
pathogenic immature B cells in the periphery [24]. This is under-
lined by the downmodulation of proinflammatory cytokines TNF-α
and IL-6, as well as MIF after blockade of CD74 on B cells. Alter-
natively, defective processing of CD74 results in the accumulation
of an N-terminal fragment, which interferes with B-cell recep-
tor signaling to suppress B-cell maturation in an MHC class II-
independent manner [9, 25, 26]. In addition to these cell-intrinsic
effects, a loss of CD74 can also influence T helper cell-mediated
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Figure 3. The CXCR4hiCD74lo phenotype of B cells in early MS blood is linked to transitional and naivemature populations. (A) Used gating strategy
for the different blood B-cell subsets analyzed in B–E: transitional (IgM+CD27−CD38hiCD24hi), naive mature (IgM+CD27−CD38−/dim), IgM+CD27+
(nonclass-switched memory), IgG+CD27+, IgG+CD27−, IgA+CD27+, and IgA+CD27− B cells. Blood from RRMS (B, C; n = 15) and high-risk CIS (D, E;
n = 16) patients was used to assess CXCR4 (B, D) and CD74 (C, E) expression on these subsets. For RRMS patients, the data were measured in three
individual experiments with five RRMS patients per experiment. For high-risk CIS patients, data were measured in nine individual experiments
with 1–2 patients per experiment. The expression level on each subset was compared to that of IgG+CD27+ memory B cells. Data are shown as
mean ± SEM. Kruskal–Wallis test with Dunn’s correction for multiple comparison was used to compare groups. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
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Figure 4. Serum MIF levels are not different, while the predominant MIF expression in B cells is reduced in CIS and RRMS patients. MIF serum
levels (ng/μL) were compared between CIS patients (n = 61) and HC (n = 29; (A), as well as between low-risk CIS (n = 33) and high-risk CIS (n
= 28) subgroups (B) using ELISA. Data are measured in one single experiment. Each dot represents the mean value of one individual, measured
in duplicates. (C) Monocytes (n = 10), dendritic cells (n = 8), T cells (n = 11), and B cells (n = 10) were sorted from healthy blood and assessed
for MIF mRNA expression relative to those of 18S mRNA using qPCR. Data were collected in four independent experiments with 2–4 donors per
experiment. Similar analyses were performed for blood B cells from CIS patients (n = 18), RRMS patients (n = 19), and HC (D; n = 22), as well as
low-risk CIS (n = 13) and high-risk CIS (n = 5) groups (E). B cells of CIS patients were sorted in nine independent experiments with 2–4 patients per
experiment. B cells of HC and RRMS patients were sorted in 17 independent experiments, with 1–2 HC and 1–2 RRMS patients per experiment. MIF
and 18S mRNA expression was measured in six individual experiments, with two independent experiments per patient group. Data are shown
as mean ± SEM. Each dot represents the mean value of one individual, measured in duplicates. Student’s t-tests were used to compare groups.
(F) Correlation between MIF mRNA levels and CXCR4/CD74 surface expression ratios in B cells from patients and healthy controls (n = 30). B cells
were sorted, mRNA was measured in duplicates, and surface expression was analyzed in six independent experiments with 2 HC and 2–4 patients
per experiment. r = Spearman’s correlation; *p < 0.05, **p < 0.01, ****p < 0.0001.
selection of naive mature B cells via altered MHC class II antigen
presentation [27].
In contrast to CD74, CXCR4was found to be themost abundant
on naive B cells, which controls their development in germinal
centers. CXCR4hi B cells are localized in the dark zone to undergo
somatic hypermutation, whereas antigen- and T helper cell-based
selection of CXCR4lo B cells occurs in the light zone [28, 29]. Our
data show that blocking of CXCR4 signaling in B cells increases
CD95 (Fas) expression, which is essential for the elimination of
autoreactive clones by T helper cells [30]. Hence, it may be specu-
lated that overexpression of CXCR4 on B cells as observed in early
MS results in the escape of naive populations from T helper cell-
based selection in the light zone, via reduced Fas expression and
enhanced migration to the dark zone. Central tolerance check-
points were not defective in MS patients [3], making it unlikely
that the abundance of CXCR4 affects precursor B-cell selection in
the bone marrow [31]. In vivo studies need to be performed in
the future to confirm these roles of CD74 and CXCR4 in peripheral
B-cell tolerance in MS.
To our knowledge, the coregulation of MIF, CD74, and CXCR4
in human B cells and MS patients has never been studied before.
Although abundantly expressed by B cells compared to other
immune populations, MIF is downregulated in blood B cells from
early MS patients. This downregulation links to the survival of
autoreactive naive B cells, as seen in atherosclerotic mice [13]
and MS [3], and coincides with decreased CD74 and increased
CXCR4 surface expression, as part of a tightly controlled reg-
ulation loop in B cells. The reciprocal expression of CD74 and
CXCR4 was supported by the increased migration capacity of B
cells toward CXCL12 after inhibition of CD74 [12, 32]. Since MIF
has a higher affinity for CD74 than for CXCR4 [7, 10], a pos-
sible underlying mechanism of this reciprocal expression is that
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Figure 5. Interference with MIF signaling pathways reveals mutual regulation of CD74, CXCR4, and MIF expression in in vitro-activated B cells. B
cells sorted from CIS, RRMS, and HC blood (n = 9–12 per group) were activated in vitro for 24 h using anti-IgM and analyzed for MIF expression (A;
qPCR) and secretion into culture media (B; ELISA). Stimulations have been done in three individual experiments with 3–4 patients per group per
experiment. Each dot represents the mean value of one individual, measured in duplicates. (C) In vitro-activated B cells from healthy blood were
treated with and without MIF inhibitor ISO-1 for 24 h and assessed for CXCR4 and CD74 surface expression using FACS (n = 6). Stimulations have
been done in three individual experiments with two controls per group per experiment. (D, E) The human B-cell line Raji (CD74hi) was transfected
with three distinct MIF shRNA constructs and compared with scrambled controls for MIF mRNA levels (D) and the percentage of CD74hi cells (E)
at day 3 (n = 5). Data were measured in five individual experiments with one set of scrambled and three different shRNA’s per experiment. In
vitro-activated B cells were also evaluated for CXCR4 (F, n = 7), CD74 (G, n = 7) and MIF mRNA (H, n = 5–6, measured in duplicates) expression
after 24 h treatment with anti-CD74 (LN2) or isotype antibody (F, H) and CXCR4 antagonist AMD3100 (G, H). Stimulations have been done in three
individual experiments with 2–3 controls per group per experiment. All used controls were set at 1 (dotted line). Data are shown as mean ± SEM.
Paired t-tests were performed to compare groups. *p < 0.05, **p < 0.01, ***p < 0.001.
MIF-mediated endocytosis of CD74 results in interaction with the
adaptor molecule β-arrestin, thereby preventing binding to and
internalization of CXCR4 [33–35] (Supporting Information Fig. 5).
Extracellular MIF levels were not different in the blood of
early MS patients. However, previous studies showed increased
levels of MIF in MS CSF [36] as well as in MS lesions and not
normal-appearing white matter [37]. This suggests that local
MIF production predominantly attracts CXCR4hi B cells from the
blood [10, 12] to mediate early MS disease activity. Another
CXCR4 ligand, CXCL12, was also found to be abundant in MS CSF,
but did not correlate to local B-cell infiltration and activation [38].
After recruitment to the CNS, CXCR4hiCD74lo B cells will probably
be activated, resulting in increased CD74 expression and MIF pro-
duction. CD74 triggering by autocrine MIFmay then enhance their
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Figure 6. CD74 and CXCR4 on human B cells differentially control proinflammatory gene expression, proliferation, and sensitivity to Fas-mediated
apoptosis. B cells from healthy blood were in vitro-activated with a-IgM and subsequently treated with anti-CD74 antibody (LN2) or AMD3100.
Data were compared to their respective controls for relative NF-κB, IL-6, and TNF-α mRNA expression after 24 h using qPCR (A, n = 4–6, measured
in duplicates), as well as CFSE-based proliferation (B and C, n = 5) and Fas (CD95) surface levels (D, n = 5) after 3 days using FACS. Stimulations
have been done in three individual experiments with two controls per group per experiment. All used controls were set at 1 (dotted line). Data are
shown as mean ± SEM. Paired t-tests were performed to compare groups. *p < 0.05, **p < 0.01.
ability to proliferate, as shown for tumor cells [39], and produce
proinflammatory cytokines to mediate CNS pathology in MS.
This study shows that MIF and MIF receptors CD74 and CXCR4
are coordinately expressed in B cells to control their inflammatory,
proliferative, and apoptotic potential in humans. The dysregu-
lation of this B cell-intrinsic loop in early MS pleads for future
studies on the processing and cooperation of CD74 and CXCR4
during autoreactive B-cell development. Also more insights into
the effects of autocrine and T helper cell-derived MIF on their
development will lead to better understanding of the role of B
cells as central players in MS and other autoimmune diseases.
Materials and Methods
Patients
Patient characteristics are summarized in Supporting Information
Table 1. All clinically isolated syndrome (CIS) and relapsing-
remitting MS (RRMS) patients as well as healthy controls (HC)
were included in MS Center ErasMS at Erasmus MC (Rotterdam,
The Netherlands). CIS was defined as a first clinical attack of
demyelination in the CNS [14]. Clinically definite MS (CDMS)
was diagnosed when a patient experienced two attacks with clin-
ical evidence of two separate lesions according to the Poser crite-
ria [40]. CIS patients were sampled within 4 months after their
first attack. From our prospective cohort, we selected CIS patients
who did not develop CDMS for at least 5 years of follow-up (low-
risk CIS) and CIS patients who were diagnosed with CDMS within
1 year after CIS diagnosis (high-risk CIS). Fatigue severity was
assessed using Krupp’s fatigue severity scale [41]. RRMS patients
were diagnosed according to the McDonalds criteria [42] and
were age- and gender-matched with healthy control subjects. For
functional studies, buffy coats (Sanquin, Amsterdam, The Nether-
lands) were obtained from healthy volunteers. All patients and
controls gave written informed consent and study protocols were
approved by the medical ethics committee of the Erasmus MC.
Peripheral blood sampling
PBMCs and plasma were isolated fromwhole blood with the use of
CPTTM heparin tubes, while serum was isolated using coagulation
tubes (both BD Biosciences, San Jose, CA). Samples were pro-
cessed according to the manufacturer’s instructions. PBMCs were
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stored in liquid nitrogen; plasma and serum were stored in –80°C
until analysis.
Human MIF ELISA
ELISAwas used tomeasure humanMIF levels in serum and plasma
using the four-span approach, as previously described [43]. In
brief, anti-human MIF polyclonal antibodies raised in chicken and
rabbit were used as capture and trapping antibodies. Microtiter
plates were coated with a duck anti-chicken antibody. A HRP-
labeled goat anti-rabbit antibody was used for the detection. Dis-
tinct concentrations of rhMIF (R&D Systems, Minneapolis, MN)
were used to generate a standard curve. The analytic sensitivity
of the human MIF ELISA was 39 pg/mL and the coefficients of
variation were 6% for intrarun and 12% for interrun.
Flow cytometry and cell sorting
In-depth flow cytometric analysis of B cells were performed using
anti-human monoclonal antibodies against CD3, CD19, CD24,
CD27, CD38, CD69, CD74, CD95, CXCR4, HLA-DR, IgA, IgD, IgG,
and IgM. Details of these antibodies are indicated in Support-
ing Information Table 2. All measurements were performed on
an LSRFortessaTM flow cytometer and data were analyzed using
FACSDiva 8.1 software (both BD Biosciences). Guidelines for the
use of flow cytometry in immunological studies have been fol-
lowed [44].
Intracellular cytokine staining
Cells were stimulated for 5 h using phorbol 12-myristate 13-
acetate (PMA; 20 ng/mL) and ionomycin (500 ng/mL, both
Sigma-Aldrich), in the presence of BD GolgiStopTM. Stimulated
cells were stained with BD HorizonTM Fixable Viability Stain 700,
fixed and permeabilized using BD Cytofix/CytopermTM according
to the provided protocol and stained for IL-6 and TNF-α (Support-
ing Information Table 2, BD Biosciences).
RNA isolation and quantitative PCR
CD19+ B cells, CD3+ T cells, CD14+ monocytes, and CD56−HLA-
DR+ dendritic cells were sorted using a high-speed cell sorter
(FACSAria IIITM; BD Biosciences), resulting in a purity of more
than 95%. Subsequently, mRNA was isolated using GenEluteTM
Mammalian RNA Kit (Sigma-Aldrich, St. Louis, MO) and reversely
transcribed into cDNA following a standard laboratory protocol
with the use of SuperScript II
R©
Reverse Transcriptase (Invitrogen,
Paisley, UK). Primers and probes were selected by using the Uni-
versal Probe Library Assay Design Centre (Roche Applied Science,
Penzberg, Germany). To determine target gene mRNA expression
levels, qPCR was performed using an Applied Biosystems 7900
Sequence Detector, which was programmed for the initial step of
2 min at 50°C and 10 min 95°C, followed by 40 thermal cycles
of 15s at 95°C and 1 min at 60°C. For the calculation of relative
mRNA levels, CT values per gene were related to standard curves,
which were generated for each gene of interest. The 18S levels
were measured as a control to normalize for RNA input. Primer
sequences are listed in Supporting Information Table 3.
In vitro activation and modulation of B cells
CD19+ B cells of healthy donors were isolated untouched by
depleting all other cell types from PBMCs using the B-cell isolation
kit II and MACS (Miltenyi Biotec, Bergisch Gladbach, Germany).
CD19+ B cells of patients and healthy controls were sorted using
FACS andwere cultured in RPMI supplemented with 10% fetal calf
serum and 1% penicillin/streptavidin for 24 hours or 3 days with
various stimuli; anti-IgM (F(ab’)2, 10 μg/mL, Jackson ImmunoRe-
search Inc., West Grove, PA) with or without MIF inhibitor ISO-
1 (100 μM, R&D Systems), a neutralizing anti-human CD74
antibody (LN2; 10 μg/mL, BD Biosciences) or AMD3100 (10
μg/mL, Sigma-Aldrich). Proliferation rates were addressed by
labeling B cells with CFSE (eBioscience, San Diego, CA) before
in vitro activation. For MIF knockdown, the human B-cell line
Raji was transfected with MIF shRNA-containing pLKO.1 con-
structs (MISSION R© shRNA Library, Sigma-Aldrich) using Nucleo-
fector Kit V from Lonza (Basel, Switzerland). Three different MIF
shRNA constructs were used: #1 GACAGGGTCTACATCAACTAT,
#2 CTACATCAACTATTACGACAT, and #3 CCTGCACAGCATCG-
GCAAGAT. MIF mRNA and CD74 surface expression was analyzed
and compared to scrambled shRNA controls at day 3.
Western blotting
Cells were lysed in radio-immunoprecipitation assay lysis buffer
supplemented with 10% complete protease inhibitor cocktail
(Roche, Mannheim, Germany) on ice for 30min, centrifuged at
4°C for 10min at 10 000 x g. Cell lysates were reduced with 10% 2-
mercaptoethanol, denatured for 5min at 95◦C, loaded onto a 10%
precast polyacrylamide gel (Bio-Rad, Hercules, CA) followed by
immunoblotting on a Immobilon-P membrane (Merck Millipore,
Darmstadt, Germany) for 1 hours at 4°C.Membranes were blocked
in 5% nonfat dry milk and incubated with rabbit anti-human NF-
κB1 p105/p50 (D7H5M, Cell signaling technology, Danvers, MA)
or mouse anti-human β-actin (AC-15; Abcam, Cambridge, UK) and
HRP-conjugated swine-anti-rabbit Ig or goat-anti-mouse Ig (Dako,
Glostrup, Denmark). Protein bands were visualized using Western
Lightning Plus-ECL (Perkin Elmer Inc., Waltham, MA).
Statistical analyses
Statistical analyses were performed using Graphpad Prism 7
(GraphPad Software Inc., San Diego, CA). Data are expressed as
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
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mean ± SEM. Datasets were tested for normal distribution. Two-
tailed t tests or ANOVAwere used to compare groups. Correlations
between two parameters were tested by using Pearson’s or Spear-
man correlation coefficients. p-values < 0.05 were considered as
statistically different.
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